デュシェンヌ型筋ジストロフィー(DMD)治療薬のグローバル市場2023-2027:生物製剤、低分子

■ 英語タイトル:Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market 2023-2027

調査会社Technavio社が発行したリサーチレポート(データ管理コード:IRTNTR71927-23)■ 発行会社/調査会社:Technavio
■ 商品コード:IRTNTR71927-23
■ 発行日:2023年7月
■ 調査対象地域:グローバル
■ 産業分野:医療
■ ページ数:約120
■ レポート言語:英語
■ レポート形式:PDF
■ 納品方式:Eメール(受注後24時間以内)
■ 販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥380,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥608,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行・送付致します。(請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能)
Technavio社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[デュシェンヌ型筋ジストロフィー(DMD)治療薬のグローバル市場2023-2027:生物製剤、低分子]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

デュシェンヌ型筋ジストロフィー(DMD)治療薬市場 2023-2027
デュシェンヌ型筋ジストロフィー(DMD)治療薬市場は、2022年から2027年にかけて23億9,767万米ドルの成長が予測され、予測期間中のCAGRは21.2%で加速すると予測されます。当レポートでは、デュシェンヌ型筋ジストロフィー(DMD)治療薬市場の全体的な分析、市場規模と予測、動向、成長促進要因、課題に加え、約25のベンダーを網羅したベンダー分析も提供しています。
当レポートでは、現在の市場シナリオ、最新動向と促進要因、市場環境全体に関する最新分析を提供しています。市場を牽引するのは、デュシェンヌ型筋ジストロフィー(DMD)患者のアンメットニーズの高さ、市場ベンダー間の戦略的提携の増加、患者支援プログラムの利用可能性などです。

Technavioのデュシェンヌ型筋ジストロフィー(DMD)治療薬市場は以下のように区分されます:

タイプ別
- 生物製剤
- 低分子

流通チャネル別
- オフライン
- オンライン

地域別
- 北米
- ヨーロッパ
- アジア
- その他の地域(ROW)

本調査では、デュシェンヌ型筋ジストロフィー(DMD)治療薬の強力なパイプラインが、今後数年間のデュシェンヌ型筋ジストロフィー(DMD)治療薬市場の成長を促進する主要な理由の1つであると特定しています。また、デュシェンヌ型筋ジストロフィー(DMD)に対する研究資金の増加や、デュシェンヌ型筋ジストロフィー(DMD)治療薬の特効薬指定は、市場の大きな需要につながるでしょう。

この調査レポートは、デュシェンヌ型筋ジストロフィー(DMD)治療薬市場を調査・分析した報告書です:
- デュシェンヌ型筋ジストロフィー(DMD)治療薬市場の規模
- デュシェンヌ型筋ジストロフィー(DMD)治療薬市場予測
- デュシェンヌ型筋ジストロフィー(DMD)治療薬市場産業分析

本レポートでは、デュシェンヌ型筋ジストロフィー(DMD)治療薬市場の主要ベンダーであるBioMarin Pharmaceutical Inc., Capricor Therapeutics Inc., CRISPR Therapeutics AG, CVS Health Corp., Daiichi Sankyo Co. Ltd., Editas Medicine Inc., Eli Lilly and Co., F. Hoffmann La Roche Ltd., FibroGen Inc., Italfarmaco Holding SPA, Nippon Shinyaku Co. Ltd., Otsuka Holdings Co. Ltd., Pfizer Inc., PTC Therapeutics Inc., Santhera Pharmaceuticals Holding AG, Sarepta Therapeutics Inc, Solid Biosciences Inc.です。また、デュシェンヌ型筋ジストロフィー(DMD)治療薬市場の分析レポートには、市場成長に影響を与える今後の動向や課題に関する情報も含まれています。これは、企業が戦略を立て、来るべき成長機会をすべて活用するのに役立つものです。

本調査は、業界の主要参加者からのインプットを含め、一次情報と二次情報を客観的に組み合わせて実施しました。当レポートでは、主要ベンダーの分析に加え、包括的な市場とベンダーの状況を掲載しています。

当レポートは、利益、価格、競争、プロモーションなどの主要パラメータの分析により、複数の情報源からのデータを調査、統合、総括する方法で、市場の詳細な姿を提示しています。また、主要な業界インフルエンサーを特定することで、市場の様々な側面を提示しています。提示されるデータは包括的で信頼性が高く、一次および二次にわたる広範な調査の結果です。市場調査レポートは、正確な市場成長を予測するために、完全な競争環境と、質的・量的調査を用いた綿密なベンダー選定方法と分析を提供します。

1 エグゼクティブサマリー
2 市場状況
3 市場規模
4 過去の市場規模
5 ファイブフォース分析
6 タイプ別市場分析
7 流通チャネル別市場分析
8 顧客状況
9 地域別状況
10 推進要因・課題・動向
11 企業状況
12 企業分析
13 付録

世界の市場調査レポート販売サイト(H&Iグローバルリサーチ株式会社運営)
*** レポート目次(コンテンツ)***

1 Executive Summary
o 1.1 Market overview
o Exhibit 01: Executive Summary – Chart on Market Overview
o Exhibit 02: Executive Summary – Data Table on Market Overview
o Exhibit 03: Executive Summary – Chart on Global Market Characteristics
o Exhibit 04: Executive Summary – Chart on Market By Geographical Landscape
o Exhibit 05: Executive Summary – Chart on Market Segmentation by Type
o Exhibit 06: Executive Summary – Chart on Market Segmentation by Distribution Channel
o Exhibit 07: Executive Summary – Chart on Incremental Growth
o Exhibit 08: Executive Summary – Data Table on Incremental Growth
o Exhibit 09: Executive Summary – Chart on Vendor Market Positioning
2 Market Landscape
o 2.1 Market ecosystem
o Exhibit 10: Parent market
o Exhibit 11: Market Characteristics
3 Market Sizing
o 3.1 Market definition
o Exhibit 12: Offerings of vendors included in the market definition
o 3.2 Market segment analysis
o Exhibit 13: Market segments
o 3.3 Market size 2022
o 3.4 Market outlook: Forecast for 2022-2027
o Exhibit 14: Chart on Global – Market size and forecast 2022-2027 ($ million)
o Exhibit 15: Data Table on Global – Market size and forecast 2022-2027 ($ million)
o Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
o Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
4 Historic Market Size
o 4.1 Global duchenne muscular dystrophy (DMD) therapeutics market 2017 – 2021
o Exhibit 18: Historic Market Size – Data Table on global duchenne muscular dystrophy (dmd) therapeutics market 2017 – 2021 ($ million)
o 4.2 Type Segment Analysis 2017 – 2021
o Exhibit 19: Historic Market Size – Type Segment 2017 – 2021 ($ million)
o 4.3 Distribution Channel Segment Analysis 2017 – 2021
o Exhibit 20: Historic Market Size – Distribution Channel Segment 2017 – 2021 ($ million)
o 4.4 Geography Segment Analysis 2017 – 2021
o Exhibit 21: Historic Market Size – Geography Segment 2017 – 2021 ($ million)
o 4.5 Country Segment Analysis 2017 – 2021
o Exhibit 22: Historic Market Size – Country Segment 2017 – 2021 ($ million)
5 Five Forces Analysis
o 5.1 Five forces summary
o Exhibit 23: Five forces analysis – Comparison between 2022 and 2027
o 5.2 Bargaining power of buyers
o Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
o 5.3 Bargaining power of suppliers
o Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
o 5.4 Threat of new entrants
o Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
o 5.5 Threat of substitutes
o Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
o 5.6 Threat of rivalry
o Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
o 5.7 Market condition
o Exhibit 29: Chart on Market condition – Five forces 2022 and 2027
6 Market Segmentation by Type
o 6.1 Market segments
o Exhibit 30: Chart on Type – Market share 2022-2027 (%)
o Exhibit 31: Data Table on Type – Market share 2022-2027 (%)
o 6.2 Comparison by Type
o Exhibit 32: Chart on Comparison by Type
o Exhibit 33: Data Table on Comparison by Type
o 6.3 Biologics – Market size and forecast 2022-2027
o Exhibit 34: Chart on Biologics – Market size and forecast 2022-2027 ($ million)
o Exhibit 35: Data Table on Biologics – Market size and forecast 2022-2027 ($ million)
o Exhibit 36: Chart on Biologics – Year-over-year growth 2022-2027 (%)
o Exhibit 37: Data Table on Biologics – Year-over-year growth 2022-2027 (%)
o 6.4 Small molecules – Market size and forecast 2022-2027
o Exhibit 38: Chart on Small molecules – Market size and forecast 2022-2027 ($ million)
o Exhibit 39: Data Table on Small molecules – Market size and forecast 2022-2027 ($ million)
o Exhibit 40: Chart on Small molecules – Year-over-year growth 2022-2027 (%)
o Exhibit 41: Data Table on Small molecules – Year-over-year growth 2022-2027 (%)
o 6.5 Market opportunity by Type
o Exhibit 42: Market opportunity by Type ($ million)
o Exhibit 43: Data Table on Market opportunity by Type ($ million)
7 Market Segmentation by Distribution Channel
o 7.1 Market segments
o Exhibit 44: Chart on Distribution Channel – Market share 2022-2027 (%)
o Exhibit 45: Data Table on Distribution Channel – Market share 2022-2027 (%)
o 7.2 Comparison by Distribution Channel
o Exhibit 46: Chart on Comparison by Distribution Channel
o Exhibit 47: Data Table on Comparison by Distribution Channel
o 7.3 Offline – Market size and forecast 2022-2027
o Exhibit 48: Chart on Offline – Market size and forecast 2022-2027 ($ million)
o Exhibit 49: Data Table on Offline – Market size and forecast 2022-2027 ($ million)
o Exhibit 50: Chart on Offline – Year-over-year growth 2022-2027 (%)
o Exhibit 51: Data Table on Offline – Year-over-year growth 2022-2027 (%)
o 7.4 Online – Market size and forecast 2022-2027
o Exhibit 52: Chart on Online – Market size and forecast 2022-2027 ($ million)
o Exhibit 53: Data Table on Online – Market size and forecast 2022-2027 ($ million)
o Exhibit 54: Chart on Online – Year-over-year growth 2022-2027 (%)
o Exhibit 55: Data Table on Online – Year-over-year growth 2022-2027 (%)
o 7.5 Market opportunity by Distribution Channel
o Exhibit 56: Market opportunity by Distribution Channel ($ million)
o Exhibit 57: Data Table on Market opportunity by Distribution Channel ($ million)
8 Customer Landscape
o 8.1 Customer landscape overview
o Exhibit 58: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
9 Geographic Landscape
o 9.1 Geographic segmentation
o Exhibit 59: Chart on Market share By Geographical Landscape 2022-2027 (%)
o Exhibit 60: Data Table on Market share By Geographical Landscape 2022-2027 (%)
o 9.2 Geographic comparison
o Exhibit 61: Chart on Geographic comparison
o Exhibit 62: Data Table on Geographic comparison
o 9.3 North America – Market size and forecast 2022-2027
o Exhibit 63: Chart on North America – Market size and forecast 2022-2027 ($ million)
o Exhibit 64: Data Table on North America – Market size and forecast 2022-2027 ($ million)
o Exhibit 65: Chart on North America – Year-over-year growth 2022-2027 (%)
o Exhibit 66: Data Table on North America – Year-over-year growth 2022-2027 (%)
o 9.4 Europe – Market size and forecast 2022-2027
o Exhibit 67: Chart on Europe – Market size and forecast 2022-2027 ($ million)
o Exhibit 68: Data Table on Europe – Market size and forecast 2022-2027 ($ million)
o Exhibit 69: Chart on Europe – Year-over-year growth 2022-2027 (%)
o Exhibit 70: Data Table on Europe – Year-over-year growth 2022-2027 (%)
o 9.5 Asia – Market size and forecast 2022-2027
o Exhibit 71: Chart on Asia – Market size and forecast 2022-2027 ($ million)
o Exhibit 72: Data Table on Asia – Market size and forecast 2022-2027 ($ million)
o Exhibit 73: Chart on Asia – Year-over-year growth 2022-2027 (%)
o Exhibit 74: Data Table on Asia – Year-over-year growth 2022-2027 (%)
o 9.6 Rest of World (ROW) – Market size and forecast 2022-2027
o Exhibit 75: Chart on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
o Exhibit 76: Data Table on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
o Exhibit 77: Chart on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
o Exhibit 78: Data Table on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
o 9.7 US – Market size and forecast 2022-2027
o Exhibit 79: Chart on US – Market size and forecast 2022-2027 ($ million)
o Exhibit 80: Data Table on US – Market size and forecast 2022-2027 ($ million)
o Exhibit 81: Chart on US – Year-over-year growth 2022-2027 (%)
o Exhibit 82: Data Table on US – Year-over-year growth 2022-2027 (%)
o 9.8 Germany – Market size and forecast 2022-2027
o Exhibit 83: Chart on Germany – Market size and forecast 2022-2027 ($ million)
o Exhibit 84: Data Table on Germany – Market size and forecast 2022-2027 ($ million)
o Exhibit 85: Chart on Germany – Year-over-year growth 2022-2027 (%)
o Exhibit 86: Data Table on Germany – Year-over-year growth 2022-2027 (%)
o 9.9 UK – Market size and forecast 2022-2027
o Exhibit 87: Chart on UK – Market size and forecast 2022-2027 ($ million)
o Exhibit 88: Data Table on UK – Market size and forecast 2022-2027 ($ million)
o Exhibit 89: Chart on UK – Year-over-year growth 2022-2027 (%)
o Exhibit 90: Data Table on UK – Year-over-year growth 2022-2027 (%)
o 9.10 Canada – Market size and forecast 2022-2027
o Exhibit 91: Chart on Canada – Market size and forecast 2022-2027 ($ million)
o Exhibit 92: Data Table on Canada – Market size and forecast 2022-2027 ($ million)
o Exhibit 93: Chart on Canada – Year-over-year growth 2022-2027 (%)
o Exhibit 94: Data Table on Canada – Year-over-year growth 2022-2027 (%)
o 9.11 China – Market size and forecast 2022-2027
o Exhibit 95: Chart on China – Market size and forecast 2022-2027 ($ million)
o Exhibit 96: Data Table on China – Market size and forecast 2022-2027 ($ million)
o Exhibit 97: Chart on China – Year-over-year growth 2022-2027 (%)
o Exhibit 98: Data Table on China – Year-over-year growth 2022-2027 (%)
o 9.12 Market opportunity By Geographical Landscape
o Exhibit 99: Market opportunity By Geographical Landscape ($ million)
o Exhibit 100: Data Tables on Market opportunity By Geographical Landscape ($ million)
10 Drivers, Challenges, and Trends
o 10.1 Market drivers
o 10.2 Market challenges
o 10.3 Impact of drivers and challenges
o Exhibit 101: Impact of drivers and challenges in 2022 and 2027
o 10.4 Market trends
11 Vendor Landscape
o 11.1 Overview
o 11.2 Vendor landscape
o Exhibit 102: Overview on Criticality of inputs and Factors of differentiation
o 11.3 Landscape disruption
o Exhibit 103: Overview on factors of disruption
o 11.4 Industry risks
o Exhibit 104: Impact of key risks on business
12 Vendor Analysis
o 12.1 Vendors covered
o Exhibit 105: Vendors covered
o 12.2 Market positioning of vendors
o Exhibit 106: Matrix on vendor position and classification
o 12.3 Capricor Therapeutics Inc.
o Exhibit 107: Capricor Therapeutics Inc. – Overview
o Exhibit 108: Capricor Therapeutics Inc. – Product / Service
o Exhibit 109: Capricor Therapeutics Inc. – Key offerings
o 12.4 CRISPR Therapeutics AG
o Exhibit 110: CRISPR Therapeutics AG – Overview
o Exhibit 111: CRISPR Therapeutics AG – Product / Service
o Exhibit 112: CRISPR Therapeutics AG – Key offerings
o 12.5 Daiichi Sankyo Co. Ltd.
o Exhibit 113: Daiichi Sankyo Co. Ltd. – Overview
o Exhibit 114: Daiichi Sankyo Co. Ltd. – Product / Service
o Exhibit 115: Daiichi Sankyo Co. Ltd. – Key news
o Exhibit 116: Daiichi Sankyo Co. Ltd. – Key offerings
o 12.6 Editas Medicine Inc.
o Exhibit 117: Editas Medicine Inc. – Overview
o Exhibit 118: Editas Medicine Inc. – Product / Service
o Exhibit 119: Editas Medicine Inc. – Key offerings
o 12.7 F. Hoffmann La Roche Ltd.
o Exhibit 120: F. Hoffmann La Roche Ltd. – Overview
o Exhibit 121: F. Hoffmann La Roche Ltd. – Business segments
o Exhibit 122: F. Hoffmann La Roche Ltd. – Key news
o Exhibit 123: F. Hoffmann La Roche Ltd. – Key offerings
o Exhibit 124: F. Hoffmann La Roche Ltd. – Segment focus
o 12.8 Italfarmaco Holding SPA
o Exhibit 125: Italfarmaco Holding SPA – Overview
o Exhibit 126: Italfarmaco Holding SPA – Product / Service
o Exhibit 127: Italfarmaco Holding SPA – Key offerings
o 12.9 Nippon Shinyaku Co. Ltd.
o Exhibit 128: Nippon Shinyaku Co. Ltd. – Overview
o Exhibit 129: Nippon Shinyaku Co. Ltd. – Business segments
o Exhibit 130: Nippon Shinyaku Co. Ltd. – Key offerings
o Exhibit 131: Nippon Shinyaku Co. Ltd. – Segment focus
o 12.10 Otsuka Holdings Co. Ltd.
o Exhibit 132: Otsuka Holdings Co. Ltd. – Overview
o Exhibit 133: Otsuka Holdings Co. Ltd. – Business segments
o Exhibit 134: Otsuka Holdings Co. Ltd. – Key offerings
o Exhibit 135: Otsuka Holdings Co. Ltd. – Segment focus
o 12.11 Pfizer Inc.
o Exhibit 136: Pfizer Inc. – Overview
o Exhibit 137: Pfizer Inc. – Product / Service
o Exhibit 138: Pfizer Inc. – Key news
o Exhibit 139: Pfizer Inc. – Key offerings
o 12.12 PTC Therapeutics Inc.
o Exhibit 140: PTC Therapeutics Inc. – Overview
o Exhibit 141: PTC Therapeutics Inc. – Product / Service
o Exhibit 142: PTC Therapeutics Inc. – Key offerings
o 12.13 Santhera Pharmaceuticals Holding AG
o Exhibit 143: Santhera Pharmaceuticals Holding AG – Overview
o Exhibit 144: Santhera Pharmaceuticals Holding AG – Product / Service
o Exhibit 145: Santhera Pharmaceuticals Holding AG – Key offerings
o 12.14 Sarepta Therapeutics Inc
o Exhibit 146: Sarepta Therapeutics Inc – Overview
o Exhibit 147: Sarepta Therapeutics Inc – Product / Service
o Exhibit 148: Sarepta Therapeutics Inc – Key offerings
o 12.15 Solid Biosciences Inc.
o Exhibit 149: Solid Biosciences Inc. – Overview
o Exhibit 150: Solid Biosciences Inc. – Product / Service
o Exhibit 151: Solid Biosciences Inc. – Key offerings
o 12.16 The Cleveland Clinic Foundation
o Exhibit 152: The Cleveland Clinic Foundation – Overview
o Exhibit 153: The Cleveland Clinic Foundation – Product / Service
o Exhibit 154: The Cleveland Clinic Foundation – Key offerings
o 12.17 Wave Life Sciences Ltd.
o Exhibit 155: Wave Life Sciences Ltd. – Overview
o Exhibit 156: Wave Life Sciences Ltd. – Product / Service
o Exhibit 157: Wave Life Sciences Ltd. – Key offerings
13 Appendix
o 13.1 Scope of the report
o 13.2 Inclusions and exclusions checklist
o Exhibit 158: Inclusions checklist
o Exhibit 159: Exclusions checklist
o 13.3 Currency conversion rates for US$
o Exhibit 160: Currency conversion rates for US$
o 13.4 Research methodology
o Exhibit 161: Research methodology
o Exhibit 162: Validation techniques employed for market sizing
o Exhibit 163: Information sources
o 13.5 List of abbreviations
o Exhibit 164: List of abbreviations

Exhibits:
Exhibits1: Executive Summary – Chart on Market Overview
Exhibits2: Executive Summary – Data Table on Market Overview
Exhibits3: Executive Summary – Chart on Global Market Characteristics
Exhibits4: Executive Summary – Chart on Market By Geographical Landscape
Exhibits5: Executive Summary – Chart on Market Segmentation by Type
Exhibits6: Executive Summary – Chart on Market Segmentation by Distribution Channel
Exhibits7: Executive Summary – Chart on Incremental Growth
Exhibits8: Executive Summary – Data Table on Incremental Growth
Exhibits9: Executive Summary – Chart on Vendor Market Positioning
Exhibits10: Parent market
Exhibits11: Market Characteristics
Exhibits12: Offerings of vendors included in the market definition
Exhibits13: Market segments
Exhibits14: Chart on Global – Market size and forecast 2022-2027 ($ million)
Exhibits15: Data Table on Global – Market size and forecast 2022-2027 ($ million)
Exhibits16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits18: Historic Market Size – Data Table on global duchenne muscular dystrophy (dmd) therapeutics market 2017 – 2021 ($ million)
Exhibits19: Historic Market Size – Type Segment 2017 – 2021 ($ million)
Exhibits20: Historic Market Size – Distribution Channel Segment 2017 – 2021 ($ million)
Exhibits21: Historic Market Size – Geography Segment 2017 – 2021 ($ million)
Exhibits22: Historic Market Size – Country Segment 2017 – 2021 ($ million)
Exhibits23: Five forces analysis – Comparison between 2022 and 2027
Exhibits24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
Exhibits25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
Exhibits26: Threat of new entrants – Impact of key factors in 2022 and 2027
Exhibits27: Threat of substitutes – Impact of key factors in 2022 and 2027
Exhibits28: Threat of rivalry – Impact of key factors in 2022 and 2027
Exhibits29: Chart on Market condition – Five forces 2022 and 2027
Exhibits30: Chart on Type – Market share 2022-2027 (%)
Exhibits31: Data Table on Type – Market share 2022-2027 (%)
Exhibits32: Chart on Comparison by Type
Exhibits33: Data Table on Comparison by Type
Exhibits34: Chart on Biologics – Market size and forecast 2022-2027 ($ million)
Exhibits35: Data Table on Biologics – Market size and forecast 2022-2027 ($ million)
Exhibits36: Chart on Biologics – Year-over-year growth 2022-2027 (%)
Exhibits37: Data Table on Biologics – Year-over-year growth 2022-2027 (%)
Exhibits38: Chart on Small molecules – Market size and forecast 2022-2027 ($ million)
Exhibits39: Data Table on Small molecules – Market size and forecast 2022-2027 ($ million)
Exhibits40: Chart on Small molecules – Year-over-year growth 2022-2027 (%)
Exhibits41: Data Table on Small molecules – Year-over-year growth 2022-2027 (%)
Exhibits42: Market opportunity by Type ($ million)
Exhibits43: Data Table on Market opportunity by Type ($ million)
Exhibits44: Chart on Distribution Channel – Market share 2022-2027 (%)
Exhibits45: Data Table on Distribution Channel – Market share 2022-2027 (%)
Exhibits46: Chart on Comparison by Distribution Channel
Exhibits47: Data Table on Comparison by Distribution Channel
Exhibits48: Chart on Offline – Market size and forecast 2022-2027 ($ million)
Exhibits49: Data Table on Offline – Market size and forecast 2022-2027 ($ million)
Exhibits50: Chart on Offline – Year-over-year growth 2022-2027 (%)
Exhibits51: Data Table on Offline – Year-over-year growth 2022-2027 (%)
Exhibits52: Chart on Online – Market size and forecast 2022-2027 ($ million)
Exhibits53: Data Table on Online – Market size and forecast 2022-2027 ($ million)
Exhibits54: Chart on Online – Year-over-year growth 2022-2027 (%)
Exhibits55: Data Table on Online – Year-over-year growth 2022-2027 (%)
Exhibits56: Market opportunity by Distribution Channel ($ million)
Exhibits57: Data Table on Market opportunity by Distribution Channel ($ million)
Exhibits58: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits59: Chart on Market share By Geographical Landscape 2022-2027 (%)
Exhibits60: Data Table on Market share By Geographical Landscape 2022-2027 (%)
Exhibits61: Chart on Geographic comparison
Exhibits62: Data Table on Geographic comparison
Exhibits63: Chart on North America – Market size and forecast 2022-2027 ($ million)
Exhibits64: Data Table on North America – Market size and forecast 2022-2027 ($ million)
Exhibits65: Chart on North America – Year-over-year growth 2022-2027 (%)
Exhibits66: Data Table on North America – Year-over-year growth 2022-2027 (%)
Exhibits67: Chart on Europe – Market size and forecast 2022-2027 ($ million)
Exhibits68: Data Table on Europe – Market size and forecast 2022-2027 ($ million)
Exhibits69: Chart on Europe – Year-over-year growth 2022-2027 (%)
Exhibits70: Data Table on Europe – Year-over-year growth 2022-2027 (%)
Exhibits71: Chart on Asia – Market size and forecast 2022-2027 ($ million)
Exhibits72: Data Table on Asia – Market size and forecast 2022-2027 ($ million)
Exhibits73: Chart on Asia – Year-over-year growth 2022-2027 (%)
Exhibits74: Data Table on Asia – Year-over-year growth 2022-2027 (%)
Exhibits75: Chart on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
Exhibits76: Data Table on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
Exhibits77: Chart on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
Exhibits78: Data Table on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
Exhibits79: Chart on US – Market size and forecast 2022-2027 ($ million)
Exhibits80: Data Table on US – Market size and forecast 2022-2027 ($ million)
Exhibits81: Chart on US – Year-over-year growth 2022-2027 (%)
Exhibits82: Data Table on US – Year-over-year growth 2022-2027 (%)
Exhibits83: Chart on Germany – Market size and forecast 2022-2027 ($ million)
Exhibits84: Data Table on Germany – Market size and forecast 2022-2027 ($ million)
Exhibits85: Chart on Germany – Year-over-year growth 2022-2027 (%)
Exhibits86: Data Table on Germany – Year-over-year growth 2022-2027 (%)
Exhibits87: Chart on UK – Market size and forecast 2022-2027 ($ million)
Exhibits88: Data Table on UK – Market size and forecast 2022-2027 ($ million)
Exhibits89: Chart on UK – Year-over-year growth 2022-2027 (%)
Exhibits90: Data Table on UK – Year-over-year growth 2022-2027 (%)
Exhibits91: Chart on Canada – Market size and forecast 2022-2027 ($ million)
Exhibits92: Data Table on Canada – Market size and forecast 2022-2027 ($ million)
Exhibits93: Chart on Canada – Year-over-year growth 2022-2027 (%)
Exhibits94: Data Table on Canada – Year-over-year growth 2022-2027 (%)
Exhibits95: Chart on China – Market size and forecast 2022-2027 ($ million)
Exhibits96: Data Table on China – Market size and forecast 2022-2027 ($ million)
Exhibits97: Chart on China – Year-over-year growth 2022-2027 (%)
Exhibits98: Data Table on China – Year-over-year growth 2022-2027 (%)
Exhibits99: Market opportunity By Geographical Landscape ($ million)
Exhibits100: Data Tables on Market opportunity By Geographical Landscape ($ million)
Exhibits101: Impact of drivers and challenges in 2022 and 2027
Exhibits102: Overview on Criticality of inputs and Factors of differentiation
Exhibits103: Overview on factors of disruption
Exhibits104: Impact of key risks on business
Exhibits105: Vendors covered
Exhibits106: Matrix on vendor position and classification
Exhibits107: Capricor Therapeutics Inc. – Overview
Exhibits108: Capricor Therapeutics Inc. – Product / Service
Exhibits109: Capricor Therapeutics Inc. – Key offerings
Exhibits110: CRISPR Therapeutics AG – Overview
Exhibits111: CRISPR Therapeutics AG – Product / Service
Exhibits112: CRISPR Therapeutics AG – Key offerings
Exhibits113: Daiichi Sankyo Co. Ltd. – Overview
Exhibits114: Daiichi Sankyo Co. Ltd. – Product / Service
Exhibits115: Daiichi Sankyo Co. Ltd. – Key news
Exhibits116: Daiichi Sankyo Co. Ltd. – Key offerings
Exhibits117: Editas Medicine Inc. – Overview
Exhibits118: Editas Medicine Inc. – Product / Service
Exhibits119: Editas Medicine Inc. – Key offerings
Exhibits120: F. Hoffmann La Roche Ltd. – Overview
Exhibits121: F. Hoffmann La Roche Ltd. – Business segments
Exhibits122: F. Hoffmann La Roche Ltd. – Key news
Exhibits123: F. Hoffmann La Roche Ltd. – Key offerings
Exhibits124: F. Hoffmann La Roche Ltd. – Segment focus
Exhibits125: Italfarmaco Holding SPA – Overview
Exhibits126: Italfarmaco Holding SPA – Product / Service
Exhibits127: Italfarmaco Holding SPA – Key offerings
Exhibits128: Nippon Shinyaku Co. Ltd. – Overview
Exhibits129: Nippon Shinyaku Co. Ltd. – Business segments
Exhibits130: Nippon Shinyaku Co. Ltd. – Key offerings
Exhibits131: Nippon Shinyaku Co. Ltd. – Segment focus
Exhibits132: Otsuka Holdings Co. Ltd. – Overview
Exhibits133: Otsuka Holdings Co. Ltd. – Business segments
Exhibits134: Otsuka Holdings Co. Ltd. – Key offerings
Exhibits135: Otsuka Holdings Co. Ltd. – Segment focus
Exhibits136: Pfizer Inc. – Overview
Exhibits137: Pfizer Inc. – Product / Service
Exhibits138: Pfizer Inc. – Key news
Exhibits139: Pfizer Inc. – Key offerings
Exhibits140: PTC Therapeutics Inc. – Overview
Exhibits141: PTC Therapeutics Inc. – Product / Service
Exhibits142: PTC Therapeutics Inc. – Key offerings
Exhibits143: Santhera Pharmaceuticals Holding AG – Overview
Exhibits144: Santhera Pharmaceuticals Holding AG – Product / Service
Exhibits145: Santhera Pharmaceuticals Holding AG – Key offerings
Exhibits146: Sarepta Therapeutics Inc – Overview
Exhibits147: Sarepta Therapeutics Inc – Product / Service
Exhibits148: Sarepta Therapeutics Inc – Key offerings
Exhibits149: Solid Biosciences Inc. – Overview
Exhibits150: Solid Biosciences Inc. – Product / Service
Exhibits151: Solid Biosciences Inc. – Key offerings
Exhibits152: The Cleveland Clinic Foundation – Overview
Exhibits153: The Cleveland Clinic Foundation – Product / Service
Exhibits154: The Cleveland Clinic Foundation – Key offerings
Exhibits155: Wave Life Sciences Ltd. – Overview
Exhibits156: Wave Life Sciences Ltd. – Product / Service
Exhibits157: Wave Life Sciences Ltd. – Key offerings
Exhibits158: Inclusions checklist
Exhibits159: Exclusions checklist
Exhibits160: Currency conversion rates for US$
Exhibits161: Research methodology
Exhibits162: Validation techniques employed for market sizing
Exhibits163: Information sources
Exhibits164: List of abbreviations



*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/



※注目の調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(IRTNTR71927-23 )"デュシェンヌ型筋ジストロフィー(DMD)治療薬のグローバル市場2023-2027:生物製剤、低分子" (英文:Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market 2023-2027)はTechnavio社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。